What if TAF is merely as good as Viread but not statsig better? That’s my definition of failure in this context.
Not sure that even a minor advantage over Viread would be enough to fight generics after patent expiration. Will depend much on GILD's ability to switch patients before 2018 and then on how aggressive payors can be.
Market Data 
Markets 
AI
